Robert Larsen

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. pmc Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome
    R A Larsen
    Department of Medicine, Infectious Diseases, University of Southern California, Los Angeles, California, USA
    Antimicrob Agents Chemother 55:5624-30. 2011
  2. pmc Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis
    Robert A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 632, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 49:952-8. 2005
  3. pmc In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis
    R A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 620, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 51:343-5. 2007
  4. pmc Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis
    Robert A Larsen
    Department of Medicine Infectious Diseases, University of Southern California, Los Angeles, California 90033, USA
    Antimicrob Agents Chemother 48:985-91. 2004
  5. pmc Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans
    Robert A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 620, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 49:3297-301. 2005
  6. ncbi request reprint Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment
    Jean L Richardson
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    AIDS 18:1179-86. 2004
  7. ncbi request reprint Using patient risk indicators to plan prevention strategies in the clinical care setting
    Jean L Richardson
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 37:S88-94. 2004
  8. ncbi request reprint Effect of a brief antiretroviral adherence intervention delivered by HIV care providers
    Joel Milam
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Acquir Immune Defic Syndr 40:356-63. 2005
  9. doi request reprint Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis
    Eric Milefchik
    University of Southern California, San Diego, California, USA
    Med Mycol 46:393-5. 2008
  10. ncbi request reprint Emerging fungal pathogens in pulmonary disease
    Alejandro Sanchez
    University of Southern California, Division of Infectious Diseases, Los Angeles, California 90033, USA
    Curr Opin Pulm Med 13:199-204. 2007

Research Grants

Collaborators

Detail Information

Publications20

  1. pmc Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome
    R A Larsen
    Department of Medicine, Infectious Diseases, University of Southern California, Los Angeles, California, USA
    Antimicrob Agents Chemother 55:5624-30. 2011
    ..These exploratory results suggest that patients whose isolates show a quantitative in vitro susceptibility response below 10 CFU/ml were more likely to survive beyond day 14...
  2. pmc Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis
    Robert A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 632, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 49:952-8. 2005
    ..The half-life of MAb 18B7 in serum was approximately 53 h, while the MAb was undetectable in the cerebrospinal fluid of all patients. These data support the continued investigation of MAb 18B7 at a maximum single dose of 1.0 mg/kg...
  3. pmc In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis
    R A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 620, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 51:343-5. 2007
    ..In vitro susceptibility employed a modified broth macrodilution method. We demonstrate a strong correlation between the quantitative measures of in vitro amphotericin B susceptibility and the quantitative response observed in patients...
  4. pmc Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis
    Robert A Larsen
    Department of Medicine Infectious Diseases, University of Southern California, Los Angeles, California 90033, USA
    Antimicrob Agents Chemother 48:985-91. 2004
    ..Given the widespread availability of amphotericin B and fluconazole and the relative safety profile of fluconazole compared to that of flucytosine, the full potential of this two-drug combination deserves further evaluation...
  5. pmc Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans
    Robert A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 620, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 49:3297-301. 2005
    ..In vitro antifungal drug susceptibility testing can reliably predict the murine response to fluconazole...
  6. ncbi request reprint Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment
    Jean L Richardson
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    AIDS 18:1179-86. 2004
    ..To test the efficacy of brief, safer-sex counseling by medical providers of HIV-positive patients during medical visits...
  7. ncbi request reprint Using patient risk indicators to plan prevention strategies in the clinical care setting
    Jean L Richardson
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 37:S88-94. 2004
    ..These factors can be easily assessed and used as a basis for tailoring safer sex counseling in the clinic setting...
  8. ncbi request reprint Effect of a brief antiretroviral adherence intervention delivered by HIV care providers
    Joel Milam
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Acquir Immune Defic Syndr 40:356-63. 2005
    ..More intensive intervention is needed to improve adherence among patients who are initially less than 95% adherent...
  9. doi request reprint Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis
    Eric Milefchik
    University of Southern California, San Diego, California, USA
    Med Mycol 46:393-5. 2008
    ..Addition of flucytosine to fluconazole improved outcomes in each dosing cohort. High doses of fluconazole alone or combined with flucytosine were well tolerated...
  10. ncbi request reprint Emerging fungal pathogens in pulmonary disease
    Alejandro Sanchez
    University of Southern California, Division of Infectious Diseases, Los Angeles, California 90033, USA
    Curr Opin Pulm Med 13:199-204. 2007
    ..Invasive fungal infections of the lung have been increasing due to the increase of the population most at risk. This review aims to describe some of the emerging fungal pathogens and their complex management...
  11. doi request reprint The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization
    Stephanie L Sansom
    US Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Patient Care STDS 22:131-8. 2008
    ..IACM was associated with a significant decrease in hospital days compared to SOC and was cost saving when program costs were compared to savings in health care utilization...
  12. pmc Cryptococcus gattii in AIDS patients, southern California
    Sudha Chaturvedi
    Mycology Laboratory, Wadsworth Center, 120 New Scotland Avenue, Albany, NY 12208 2002, USA
    Emerg Infect Dis 11:1686-92. 2005
    ..The high prevalence of Cg was noteworthy, in view of its sporadic reports from AIDS patients in North America and its recent emergence as a primary pathogen on Vancouver Island, Canada...
  13. ncbi request reprint Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis
    Annemarie E Brouwer
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    J Infect Dis 192:681-4. 2005
    ..5 dilutions. In individual patients, there was no correlation between the rate of decline in CSF cryptococcal colony-forming unit counts and that in CSF cryptococcal antigen titers...
  14. ncbi request reprint Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients
    Catherine Diamond
    University of California Irvine Medical Center, Department of Internal Medicine, Orange, CA, USA
    J Acquir Immune Defic Syndr 39:211-8. 2005
    ..6 (95% CI 0.5-0.8, P < 0.001). Contrary to expectations, use of and adherence to ART and their consequent suppression of HIV were associated with a decreased prevalence of self-reported risky sexual behavior...
  15. ncbi request reprint Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
    Annemarie E Brouwer
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 363:1764-7. 2004
    ..We compared the fungicidal activity of combinations of these drugs for initial treatment of patients with cryptococcal meningitis...
  16. ncbi request reprint A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients
    Peter G Pappas
    University of Alabama at Birmingham, 35294 0006, USA
    Clin Infect Dis 37:634-43. 2003
    ..6 vs. 16.1), which suggests that the former subjects are more often excluded from therapeutic trials...
  17. pmc Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis
    John R Graybill
    The University of Texas Health Science Center at San Antonio, Department of Medicine, San Antonio, Texas 78229 3900, USA
    Antimicrob Agents Chemother 47:2373-5. 2003
    ..However, caspofungin is not 100% curative in candidiasis. Therefore, we evaluated combinations of fluconazole with caspofungin for murine candidemia. We could not show any benefit of combined therapy over individual antifungal drugs...
  18. ncbi request reprint Are HIV care providers talking with patients about safer sex and disclosure?: A multi-clinic assessment
    Gary Marks
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS 16:1953-7. 2002
    ..To examine HIV-positive patients' reports of whether HIV care providers ever talked with them about practicing safer sex and disclosing seropositive status to sex partners...
  19. pmc Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States
    Luis Ostrosky-Zeichner
    University of Texas Houston Medical School, Houston, Texas, USA
    Antimicrob Agents Chemother 47:3149-54. 2003
    ....
  20. ncbi request reprint Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients
    Joseph Meletiadis
    National Cancer Institute, Bethesda, MD, USA
    Med Mycol 45:513-8. 2007
    ..40% in controls). An analysis of haplotypes showed a significant difference in distribution between cases and controls overall and in Caucasians...

Research Grants1